Aurinia Pharmaceuticals (AUPH) Net Margin (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of Net Margin data on file, last reported at 44.21% in Q1 2026.

• Quarterly Net Margin rose 684.0% year-over-year to 44.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 99.99% (up 8388.0% YoY) and the FY2025 annual result came in at 101.47%, up 9902.0% from the prior year.
• Net Margin declined to 44.21% in Q1 2026, from 273.35% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 273.35% in Q4 2025 to a low of 174.01% in Q1 2022.
• A 5-year average of 9.62% and a median of 16.12% in 2022 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2022 — Net Margin soared 533791 bps — and 2023, when it plunged 855 bps.
• Tracing AUPH's Net Margin over 5 years: stood at 91.5% in 2022, then surged by 35 bps to 59.58% in 2023, then surged by 104 bps to 2.47% in 2024, then soared by 10980 bps to 273.35% in 2025, then sank by 84 bps to 44.21% in 2026.
• The last three Net Margin figures came in at 44.21% (Q1 2026), 273.35% (Q4 2025), and 42.96% (Q3 2025), per Business Quant data.